LOS ANGELES--(BUSINESS WIRE)--Abraxis BioScience, Inc. (NASDAQ:ABBI), an integrated, global biopharmaceutical company, today announced that multiple studies of ABRAXANE® for Injectable Suspension (paclitaxel protein-bound particles for injectable suspension) (albumin bound) will be presented at the 43rd Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago, June 1-5, 2007. Data will be presented from studies which highlight the potential utility of ABRAXANE (ABI-007) as a single-agent and in combination for the treatment of breast, lung and ovarian cancers.
